Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain

European Journal of Health Economics

Volumn 8, Issue 2, 2007, Pages 123-135

  Rutten Van Mölken, Maureen P M H ^a   Oostenbrink, Jan B ^a   Miravitlles, Marc ^b   Monz, Brigitta U ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HOSPITAL CLÍNIC   (Spain)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Bronchodilators; Chronic obstructive pulmonary disease (COPD); Cost effectiveness; Model; Quality adjusted life year (QALY); Spain

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ARTICLE; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; HEALTH CARE UTILIZATION; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SPAIN;

ALBUTEROL; BRONCHODILATOR AGENTS; COST-BENEFIT ANALYSIS; HUMANS; IPRATROPIUM; MARKOV CHAINS; NATIONAL HEALTH PROGRAMS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY-ADJUSTED LIFE YEARS; SCOPOLAMINE DERIVATIVES; SPAIN;

EID: 34248366557     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-007-0039-4     Document Type: Article

References (43)

1. Barnes, P.J.: Chronic obstructive pulmonary disease: new treatments for COPD. Thorax 58(9), 803-808 (2003)
2. Ayres, J.G., Price, M.J., Efthimiou, J.: Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial. Respir. Med. 97(3), 212-220 (2003)
3. Gallefoss, F., Bakke, P.S.: Cost-benefit and cost-effectiveness analysis of self-management in patients with COPD - a 1-year follow-up randomized, controlled trial. Respir. Med. 96(6), 424-431 (2002)
4. Hogan, T.J., Geddes, R., Gonzalez, E.R.: An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease. Clin. Ther. 25(1), 285-297 (2003)
5. Jones, P.W., Wilson, K., Sondhi, S.: Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation. Respir. Med. 97(1), 20-26 (2003)
6. Rutten-van Mölken, M.P.M.H., van Doorslaer, E.K.A., Jansen, M.C.C., Kerstjens, H.A.M., Rutten, F.F.H.: Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 151, 975-982 (1995)
7. Torrance, G., Walker, V., Grossman, R., Mukherjee, J., Vaughan, D., La Forge, J., Lampron, N.: Economic evaluation of Ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. PharmacoEconomics 16 (5 pt1), 499-520 (1999)
8. Gold, M.R., Siegel, J.E., Russell, L.B., Weinstein, M.C.: Cost-effectiveness in Health and Medicine, 1st edn. Oxford University Press, New York (1996)
9. Hjelmgren, J., Berggren, F., Andersson, F.: Health economic guidelines - similarities, differences and some implications. Value Health 4(3), 225-50 (2001)
10. International Society For Pharmacoeconomics & Outcomes Research (ISPOR): Pharmacoeconomic guidelines around the world. http://www.ispor.org/ PEguidelines/index.as. Accessed July 2005
11. National Institute for Clinical Excellence: Guide to the Methods of Technology Appraisal. NICE, London (2004)
12. Casaburi, R., Mahler, D.A., Jones, P.W., Wanner, A., San, P.G., ZuWallack, R.L., Menjoge, S.S., Serby, C.W., Witek, T.J., Jr.: A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 19(2), 217-224 (2002)
13. Vincken, W., van Noord, J.A., Greefhorst, A.P., Bantje, T.A., Kesten, S., Korducki, L., Cornelissen, P.J.: Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur. Respir. J. 19(2), 209-216 (2002)
14. Brusasco, V., Hodder, R., Miravitlles, M., et al.: Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58(5), 399-404 (2003)
15. Briggs, A.H., Sculpher, M.: An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 13(4), 397-409 (1998)
16. Briggs, A.: Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Health 8(1):1-2 (2005)
17. Oostenbrink, J.B., Rutten-van Mölken, M.P.M.H., Monz, B.U., FitzGerald, J.M.: Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 8(1), 32-46 (2005)
18. Scanlon, P.D., Connett, J.E., Waller, L.A., Altose, M.D., Bailey, W.C., Buist, A.S.: Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am. J. Respir. Crit. Care Med. 161, 381-390 (2000)
19. Miravitlles, M., Murio, C., Guerrero, T.: Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group. Eur. Respir. J. 17(5), 928-933 (2001)
20. Miravitlles, M., Ferrer, M., Pont, A., Zalacain, R., Alvarez-Sala, J.L., Masa, F., Verea, H., Murio, C., Ros, F., Vidal, R.: Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 59(5), 387-395 (2004)
21. Decramer, M., Celli, B.R., Tashkin, D.P., Pauwels, R.A., Burkhart, D., Cassino, C., Kesten, S.: Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the Uplift trial. J. Chron. Obstruct. Pulm. Dis. 1(2), 303-312 (2004)
22. Badia, X., Roset, M., Herdman, M., Kind, P.: A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. Med. Decis. Making 21(1), 7-16 (2001)
23. Paterson, C., Langan, C.E., McKaig, G.A., Anderson, P.M., Maclaine, G.D., Rose, L.B., Walker, S.J., Campbell, M.J.: Assessing patient outcomes in acute exacerbations of chronic bronchitis: the measure your medical outcome profile (MYMOP), medical outcomes study 6-item general health survey (MOS-6A) and EuroQol (EQ-5D). Qual. Life Res. 9(5), 521-527 (2000)
24. Spencer, S., Jones, P.W.: Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 58(7), 589-593 (2003)
25. Miravitlles, M., Murio, C., Guerrero, T., Gisbert, R.: Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 121(5), 1449-1455 (2002)
26. Miravitlles, M., Murio, C., Guerrero, T., Gisbert, R.: Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 123(3), 784-791 (2003)
27. Institute for Medical Statistics (IMS) Health: El Marcado Farmaceutico Spain. http://www.imsportal.com (restricted access). Accessed July 2005
28. Rovira, J., Antonanzas, F.: Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation. Pharmacoeconomics 8(3), 245-252 (1995)
29. Briggs, A.H.: Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17(5), 479-500 (2000)
30. van Hout, B.A., Al, M.J., Gordon, G.S., Rutten, F.F.H.: Costs, effects and c/e-ratios alongside a clinical trial. Health Econ. 3, 309-319 (1994)
31. Briggs, A.H., Fenn, P.A.: Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ. 7, 723-740 (1998)
32. Fenwick, E., Claxton, K., Sculpher, M.: Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 10(8), 779-787 (2001)
33. Stinnett, A.A., Mullahy, J.: Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med. Decis. Making 18(2 Suppl), S68-S80 (1998)
34. Esteban, C., Moraza, J., Aburto, M., Quintana, J.M., Capelastegui, A.: Description of a sample of patients with chronic obstructive pulmonary disease treated at hospital-supervised respiratory clinics at primary care centers. Arch. Bronconeumol. 39(11), 485-490 (2003)
35. Sacristan, J.A., Oliva, J., Del Llano, J., Prieto, L., Pinto, J.L.: What is an efficient health technology in Spain? (in Spanish). Gac. Sanit. 16(4), 334-343 (2002)
36. Langley, P.C.: The NICE reference case requirement: implications for drug manufacturers and health systems. Pharmacoeconomics 22(4), 267-271 (2004)
37. Chapman, R.H., Stone, P.W., Sandberg, E.A., Bell, C., Neumann, P.J.: A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies. Med. Decis. Making 20(4), 451-67 (2000)
38. Laupacis, A., Feeny, D., Detsky, A.S., Tugwell, P.X.: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can. Med. Assoc. J. 146(4), 473-481 (1992)
39. Anzueto, A., Tashkin, D., Menjoge, S., Kesten, S.: One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium, Pulm. Pharmacol. Ther. 18(2), 75-81 (2005)
40. Donaldson, G.C., Seemungal, T.A., Bhowmik, A., Wedzicha, J.A.: Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57(10), 847-852 (2002)
41. Kanner, R.E., Anthonisen, N.R., Connett, J.E.: Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am. J. Respir. Crit. Care Med. 164(3), 358-364 (2001)
42. Sculpher, M.J., Buxton, M.J.: The episode-free day as a composite measure of effectiveness: an illustrative economic evaluation of formoterol versus salbutamol in asthma therapy. Pharmacoeconomics 4(5), 345-352 (1993)
43. Richter, A., Anton, S.E., Koch, P., Dennett, S.L.: The impact of reducing dose frequency on health outcomes. Clin. Ther. 25(8), 2307-2335 (2003)